Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Rhea-AI Summary
Aspire Biopharma Holdings (NASDAQ:ASBP), a developer of patent-pending drug delivery technology, has announced its participation in the upcoming Sidoti Virtual Investor Conference. CEO Kraig Higginson will deliver a presentation on May 21, 2025, at 2:30 PM Eastern. The company will also host one-on-one meetings with investors on May 21-22, 2025.
Interested participants can access the virtual presentation through Sidoti's registration link, and a replay will be available on Aspire's investor relations website. This conference provides an opportunity for investors to learn more about Aspire's multi-faceted drug delivery technology and engage directly with management.
Positive
- None.
Negative
- None.
HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on May 21 at 2:30 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_q62DwzilROyKt-kOh_GJDQ
One-on-One Meetings
Inspire will also host virtual one-on-ones with investors on Wednesday, May 21 and Thursday, May 22, 2025. To register for the presentation or one-on ones, visit https://sidoti.com/events.
A replay of the presentation will be available on the investor relations section of Inspire's website at https://ir.aspirebiolabs.com/events/
About Aspire Biopharma, Inc.
Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.
Safe Harbor Statement
Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Aspire Biopharma Holdings, Inc.
Contact
TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Aspire Biopharma (ASBP) presenting at the Sidoti Virtual Investor Conference?
Who will be presenting for Aspire Biopharma at the Sidoti Conference?
How can investors access Aspire Biopharma's Sidoti Conference presentation?
What are the dates for one-on-one meetings with Aspire Biopharma management?
